WeChatshare
7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition

You can share it to WeChat via the Qr code.

Eventsshare
7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition

Enter the applet sharing event using WeChat scan.

Event Background

In the context of being part of ICH, the biopharmaceutical industry in China has entered a new era with emerging challenges: how to develop the next generation of innovative therapeutic biologics to stand out from the competition? How to speed up from R&D to regulatory submission with differentiated product pipelines (antibodies, therapeutic vaccines, cell and gene therapy products, virus products)?How to make compliance with regulatory requirements when making bioprocess improvement changes? How to accelerate the clinical development of innovative biopharma and biosimilars? What factors should be considered in the mass production and plant construction of biopharma?

As the most influential annual biopharma event in China, the 7th BioCon 2020 will be held on July 7-9 in CECIS-Shanghai, with higher speaker quality, deeper insights, cutting-edge regulation interpretation, and real technical case studies from leading biopharma players. Comprehensive topics will cover from drug discovery to IND, from the laboratory test to industrialization, from preclinical development to clinical development, from process development to commercial production, from NDA to commercial launch . The event aims to build a professional platform for regulatory discussions, technical exchanges, product displays, project cooperation from China and overseas, hence helping industry players to succeed in the fast growing Chinese biopharmaceutical industry!


001.jpg

What’s New in BioCon 2020?

结构-02.png Interpreting the latest guidelines of global regulations and China's new policies to help biopharma companies to navigate in the changing
regulatory environment

结构-02.png Focusing on the development of hot product portfolios -- the next generation of polyclonal antibodies, ADC, nano-antibodies, cell therapy, oncolytic viruses, recombinmant proteins and etc. 

结构-02.png Sharing the best practices of global product submissions with multi-centerclinical trials worldwide

结构-02.png Analyzing the latest discoveries and achievements of combined therapy for cancer

结构-02.png Introducing the application of new antibody development platforms to improve R&D efficiency with lower cost 

结构-02.png Discussing the optimized bioprocess changing paths and the supervision of post-process changing requirements

结构-02.png Exploring cost-effective biopharma plant design and construction in compliance with GMP requirements

13+ Sub-Forums, Covering the Whole Biopharma Discovery and Development Cycle

结构en-02.jpg

Rewiew of BioCon
h-01.png            

BioCon China is dedicated to establishing a robust idea-exchanging and business-cooperating platform for global regulatory agencies, and worldwide leading biotech companies and Asian biopharmaceutical enterprises. In the previous activities, BioCon China has accumulated 4000+ global industrial participants, 320+ leading products, solution and service providers, and 450+ prominent speakers to join the annual grand events.

Biocon 2020 Speaker(Part)
  • Member of Chinese Academy of  EngineeringZhinan Chen
    Zhinan Chen
    Member of Chinese Academy of Engineering
  • Former Director of Quantitative, Pharmacology of FDAYaning Wang
    Yaning Wang
    Former Director of Quantitative, Pharmacology of FDA
  • Director of Shanghai Institute of ImmunologySu Bing
    Su Bing
    Director of Shanghai Institute of Immunology
  • Secretary of the Party Committee of institutes of biomedical sciencesChu Yiwei
    Chu Yiwei
    Secretary of the Party Committee of institutes of biomedical sciences
  • researcher at the Institute of Microbiology, Chinese Academy of Sciences.Yan Jinghua
    Yan Jinghua
    researcher at the Institute of Microbiology, Chinese Academy of Sciences.
  • Director of the Research Center for Drug Safety Evaluation of Shanghai Institute of Medicine, Chinese Academy of SciencesRen Jin
    Ren Jin
    Director of the Research Center for Drug Safety Evaluation of Shanghai Institute of Medicine, Chinese Academy of Sciences
  • Director of the Nanoantibody Research Center of Guangxi Medical University and Vice President of the Affiliated Stomatological HospitalLu Xiaoling
    Lu Xiaoling
    Director of the Nanoantibody Research Center of Guangxi Medical University and Vice President of the Affiliated Stomatological Hospital
  • CEO, Fosun Kite Biotechnology Co. LtdRichard Wang
    Richard Wang
    CEO, Fosun Kite Biotechnology Co. Ltd
    Richard received degrees of B.S of Cell Biology from the University of Science & Technology of China, Ph.D. of Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, Cincinnati in the US. He obtained his postdoctoral training at the National Institutes of Health, Baltimore, USA. Richard now is the CEO of Fosun Kite Biotechnology . Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients. Richard is very experienced in biopharmaceutical industry . Having spent close to 20 years in R&D and management positions in both the US and China, he has taken senior roles and increasing leadership responsibilities in Procter & Gamble Pharmaceutical, Bristol-Myers Squibb in the US, AstraZeneca Innovation Center and GSK R&D Center in China. Prior to Fosun Kite, Richard was the Chief Operation Officer of Cellular Biomedicine Group (NASDAQ: CBMG), where he was in charge of the company’s immunotherapy pipeline including manufacturing, clinical development and registration, and the stem cell business unit.
  • President of RemeGenDaotian Fu
    Daotian Fu
    President of RemeGen
  • Co founder, Shanghai Henlius  Biotech, Inc.Shigao Liu
    Shigao Liu
    Co founder, Shanghai Henlius Biotech, Inc.
  • Chairman and CEO of PersonGen.AnkeYang Lin
    Yang Lin
    Chairman and CEO of PersonGen.Anke
  • Co-founder & Chief  Scientific Officer,  Nanjing Legend  Biotechnology Co., LtdXiaohu Fan
    Xiaohu Fan
    Co-founder & Chief Scientific Officer, Nanjing Legend Biotechnology Co., Ltd
  • President of R&D, I-MabJoan Huaqiong Shen
    Joan Huaqiong Shen
    President of R&D, I-Mab
  • CEO of  CarsGenLi Zonghai
    Li Zonghai
    CEO of CarsGen
  • CEO of  JW therapeuticsYiping Li
    Yiping Li
    CEO of JW therapeutics
  • founder, chairman and CEO of  GMaxBioJing Shuqian
    Jing Shuqian
    founder, chairman and CEO of GMaxBio
  • founder, chairman and CEO of  StemiRNALi Hangwen
    Li Hangwen
    founder, chairman and CEO of StemiRNA
  • founder and CEO of  SinoMab BioScience LimitedLiang Ruian
    Liang Ruian
    founder and CEO of SinoMab BioScience Limited
  • director of r&d and bioimmunology at sanofi (USA)Yang  Zhiyong
    Yang Zhiyong
    director of r&d and bioimmunology at sanofi (USA)
  • chairman and CEO of RactigenLi  Longcheng
    Li Longcheng
    chairman and CEO of Ractigen
  • chairman and CEO of  HangZhou  DAC  biotechZhao  Yongxin
    Zhao Yongxin
    chairman and CEO of HangZhou DAC biotech
  • chairman of  Binhui-biotechLiu  Binlei
    Liu Binlei
    chairman of Binhui-biotech
  • Founder, Chairman and CEO, ImmViraGuoying Zhou
    Guoying Zhou
    Founder, Chairman and CEO, ImmVira
    周国瑛,中科院上海生化所博士,国家千人,2019年国际“抗病毒女科学家奖”唯一获得者,2021年中国十大杰出女企业家,1999-2014年芝加哥大学从事疱疹病毒研究,在抗病毒感染与疱疹溶瘤病毒肿瘤免疫治疗研究领域深耕近30年。靶向疱疹溶瘤病毒国际发明人,主持十三五国家重大新药创制等科研项目,发表50余篇,国际发明专利获得授权20余项,任多个国际期刊编委和审稿。 周博士在亦诺微医药主领溶瘤病毒的免疫治疗与靶向治疗的多管线平台型药物研发,产品覆盖实体瘤与血液肿瘤,用药途径从瘤内注射到静脉注射,单药及各种联合用药,公司首批三款溶瘤病毒产品在中美两地进行I期、II期共7项包括单药和联用的临床研究。此外,公司还成功研发出专用于跟CAR-T联用治疗实体瘤的溶瘤病毒新产品,并建设和投入使用了符合IND申报和I期临床的GMP车间。同期,亦诺微开发了非复制病毒载体的肿瘤疫苗和生物工程化外泌体创新管线,同步聚焦肿瘤与非肿瘤全自主创新药研发。
  • Founder&CEO, Medilink TherapeuticsTongtong Xue
    Tongtong Xue
    Founder&CEO, Medilink Therapeutics
  • co-founder and CEO of  BJ Bioscience IncZhang  Haizhou
    Zhang Haizhou
    co-founder and CEO of BJ Bioscience Inc
  • CMO  of Zai Lab LimitedHei Yongjiang
    Hei Yongjiang
    CMO of Zai Lab Limited
  • vice President of  Innovent  BioLiu Junjian
    Liu Junjian
    vice President of Innovent Bio
  • chairman and President of  Ascom bio-pharmaceutical & Jianshun BioLuo  Shun
    Luo Shun
    chairman and President of Ascom bio-pharmaceutical & Jianshun Bio
  • vice President and chief technology officer of ask-pharmLv Yuefeng
    Lv Yuefeng
    vice President and chief technology officer of ask-pharm
  • founder of  Waterstone chinaZhang  Faming
    Zhang Faming
    founder of Waterstone china
  • CSO, Senior VP, Head of Research & Early Clinical Development at CStonepharmaArchie Tse
    Archie Tse
    CSO, Senior VP, Head of Research & Early Clinical Development at CStonepharma
  • senior vice President of  Qianyan bioLu Rongjian
    Lu Rongjian
    senior vice President of Qianyan bio
  • chairman and CEO of  MEDx (Suzhou)  Translational  Medicine  Co.,LtdZhang  Yafei
    Zhang Yafei
    chairman and CEO of MEDx (Suzhou) Translational Medicine Co.,Ltd
    张亚飞博士(美国辛辛那提大学博士)拥有30年的药物研发经验及转化医学和诊断行业经验,现任迈杰转化医学研究(苏州)有限公司董事长和CEO。之前相继担任美国方达医药中国总经理和集团资深副总裁、诺华中国研发中心部门总监、美国OSI医药集团部门总监以及美国辉瑞研发中心经理。张博士是全球生命科学和医疗健康产业领域华人精英组织百华协会 (Bayhelix)的一员,也是江苏省生物技术协会副理事长,同时是中国生物工程协会精准医疗和伴随诊断专业委员会发起者之一及副主任委员。 荣获了园区创业创新领军人才,金鸡湖双百人才计划, 江苏省双创人才,江苏省海外高层次人才和江苏省优秀企业家称号。
  • Founder & CEO, JADE BioMedicalClaudia Lin
    Claudia Lin
    Founder & CEO, JADE BioMedical
    千人计划企业创新专家,出生于上海,曾就学于复旦大学,之后获美国加州大学伯克利分校细胞和分子生物学博士学位。在博士后培训期间及之后,林博士对基础型和转化型癌症进行过深入研究。在过去15年里,她的职业生涯主要聚焦于化学、生产和控制尤其是质量管理等方面。她曾在基因泰克/罗氏担任多种质量管理领导的岗位职责,包括临床研发阶段的QA,QC部门,以及罗氏全球商业化生物产品技术转移、年度产品质量回顾等;之后,林博士在加州的拜耳医药生物技术分部担任质量总监,全面负责所有临床开发阶段中质量体系及产品质量。林博士曾参与全球领先的单抗产品上市工作,包括Avastin, Perjeta, Kavoltry。林博士在欧美亚同行中享有很好的声誉,活跃与世界级的专业会议讲台。2015年初,林博士归国先后担任两家中国知名生物制药企业高管,负责GMP合规与质量管理。2017年5月,林博士创立苏州驾玉生物医药有限公司,专注生物制药行业的质量管理及检测承包服务。
  • general manager of  GenoimmuneLi  Bo
    Li Bo
    general manager of Genoimmune
  • deputy general manager of  Hengrui  MedicineLiu Xun
    Liu Xun
    deputy general manager of Hengrui Medicine
  • vice President  of  Gracell  BioJeffery He
    Jeffery He
    vice President of Gracell Bio
  • senior vice President of Teruisi  PharmRan  Zhaoxiang
    Ran Zhaoxiang
    senior vice President of Teruisi Pharm
  • vice President of quality science  , chuang sheng groupShi  Liming
    Shi Liming
    vice President of quality science , chuang sheng group
  • general manager of Shanghai TofflonCheng  Jinsheng
    Cheng Jinsheng
    general manager of Shanghai Tofflon
  • SVP, Head of CMC, Harbour BioMedMinmin Qin
    Minmin Qin
    SVP, Head of CMC, Harbour BioMed
  • CEO and Co-founder, Exegenesis BioZhenhua Wu
    Zhenhua Wu
    CEO and Co-founder, Exegenesis Bio
  • Vice General Manager, Bioanalytical Sciences, Shanghai Henlius BiotechLinglong Zou
    Linglong Zou
    Vice General Manager, Bioanalytical Sciences, Shanghai Henlius Biotech
  • VP, BIORAY LABORATORIES IncLiang Zhang
    Liang Zhang
    VP, BIORAY LABORATORIES Inc
    Dr. Zhang liang graduated from Shanghai Institute of Biochemistry and Cell Biology, CAS. He used to be the project leader of drug research and development in Shanghai Haiyan Medical Technology CO. LTD. (Yangtze River Pharmaceutical Group). Currently, he is responsible for the development and production of cell therapy as the vice president of BIORAY LABORATORIES Inc. He has rich experience in new drug development, compliance and application, he also has extensive experience in cell therapy technology and translational systems development.
  • President of  research ,PreGeneWu  Xianhui
    Wu Xianhui
    President of research ,PreGene
  • senior director of  HenliusGong  Wei
    Gong Wei
    senior director of Henlius
  • technical director of  PersonGen.AnkeWang  Min
    Wang Min
    technical director of PersonGen.Anke
  • senior medical director, AlphamabXu  Junfang
    Xu Junfang
    senior medical director, Alphamab
  • senior director of quality assurance at  3s-guojianLi  Mengjie
    Li Mengjie
    senior director of quality assurance at 3s-guojian
  • general manager of  ObioJia  Guodong
    Jia Guodong
    general manager of Obio
  • senior medical officer of  PersonGen.AnkeMeng Huimin
    Meng Huimin
    senior medical officer of PersonGen.Anke
    MD & PhD,潍坊医学院毕业,获得医学学士学位;南方医科大学病理学专业毕业,获得医学硕士学位;苏州大学唐仲英血液学研究中心毕业,获得医学博士学位。现任博生吉医药科技(苏州)有限公司医学总监,拥有长达10余年的丰富的CAR相关技术研发、临床试验管理、以及医学方案制定等相关经验。领导与协调和各个临床研究机构的合作、推动和管理了多项CART的临床试验项目,涵盖血液瘤和实体肿瘤,其中包括博生吉自主开发的First-in-class CART细胞药物的注册临床试验。
  • Institute  of  Microbiology, Chinese  Academy  of  SciencesTan  Shuguang
    Tan Shuguang
    Institute of Microbiology, Chinese Academy of Sciences
    国家优秀青年科学基金项目获得者。研究方向为病原微生物感染的T细胞免疫应答机制、T细胞重要免疫受体的配体识别机制及肿瘤免疫治疗新策略研究。在Nature Immunology,Cell Research,Nature Communications,PNAS等杂志发表论文60余篇,申请发明专利16项,并获得11项专利授权。任中国生物工程学会抗体专业委员会委员及中国免疫学会青年工作委员会委员。
  • research and development director of  Edigene-A  Genome  Editing  CompanyFang  Riguo
    Fang Riguo
    research and development director of Edigene-A Genome Editing Company
  • quality  director of  Wuxi  shengji pharmaceuticalChen  Qiang
    Chen Qiang
    quality director of Wuxi shengji pharmaceutical
  • Testimonials
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    Partners
    Co-organizers
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    Supporters
    Retrieve E-tickets
    Please enter the ticket recipient's email or cell phone
    Retrieve
    Registration
    Preparation Stage
    Registration
    End of Event
    Choose ticket
    Type
    Price(¥)
    Sales End
    Quantity
    A tickets (April 23 ,China Biopharma Industry Summit)
    2,980
    2020-07-09 17:00
    Past Events
    B tickets (April 24 - April 25)
    3,980
    2020-07-09 17:00
    Past Events
    A + B
    4,980
    2020-07-09 17:00
    Sold Out
    C: 7月8-9日展区观摩票 (含细胞治疗、生产制造论坛入场券)
    980
    2020-07-09 17:00
    Past Events
    Price
    0